Basiliximab for IL-2-Associated Inflammatory Disorder With Atopic Dermatitis.

Options for pediatric patients with severe atopic dermatitis who do not respond to biologics remain limited. We report the case of a 10-year-old boy with severe, recalcitrant atopic dermatitis associated with episodic fever, joint pains, and elevated serum IL-2R, which responded to basiliximab. To our knowledge, this is the first reported use of basiliximab for atopic dermatitis in a pediatric patient. This case highlights the potential for basiliximab as a therapy for severe cases of atopic dermatitis and the potential for precision medicine in dermatology.